Standard BioTools (LAB) analyst forecast and price target
Analyst forecast
Consensus of 1 analyst rating
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| TD Cowen | Maintained | Hold | $1.35 from $1.55 | Nov 5, 2025 |
| Keybanc | Downgraded | Overweight → Sector Weight | — | Feb 27, 2025 |
| TD Cowen | Maintained | Buy | $2.50 from $2.75 | Oct 31, 2024 |
| TD Cowen | Maintained | Buy | $2.75 from $3.50 | Aug 1, 2024 |
| TD Cowen | Initiated Coverage | Buy | $3.50 | Apr 16, 2024 |
| Jefferies | Initiated Coverage | Buy | $3.25 | Apr 4, 2024 |
| Keybanc | Initiated Coverage | Overweight | $4.00 | Jul 12, 2023 |
Frequently asked questions
Is LAB a buy, sell, or hold?
Analysts covering Standard BioTools currently average a Hold rating: 0 buy, 1 hold and 0 sell, from 1 analyst. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on LAB?
On Nov 5, 2025, TD Cowen maintained Standard BioTools at Hold with a price target of $1.35.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.